Skip to content

The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

The Italian Registry of Pulmonary Non-tuberculous Mycobacteria

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03339063
Acronym
IRENE
Enrollment
500
Registered
2017-11-13
Start date
2017-04-21
Completion date
2022-12-31
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nontuberculous Mycobacteria

Keywords

Nontuberculous Mycobacteria, Non-tuberculous mycobacteria, NTM-PD, NTM-LD, MAC, M. avium, M. intracellulare, M. abscessus, Atypical mycobacteria, NTM

Brief summary

The Italian registry of pulmonary non-tuberculous mycobacteria (NTM) -IRENE- is an observational, multicenter, prospective, cohort study enrolling consecutive adult patients with either a NTM respiratory infection or NTM-Pulmonary Disease. The coordinating center is located at the Pulmonary Department of the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. So far, more than 35 centers, including mainly pulmonary and infectious disease departments, joined the registry. The registry has been developed to accept an unlimited number of patients and no deadlines have been decided.

Detailed description

The epidemiology of patients suffering from a pulmonary disease due to NTM (NTM-PD), which is characterized by symptomatic, progressive inflammatory lung damage and defined in 2007 in the ATS/IDSA guidelines, still remains unclear. Reporting of NTM-PD to health authorities is often not mandated in several countries and the current estimates have been obtained from sentinel surveillance or laboratory-based studies, retrospective cohort studies, or audits of administrative databases. Until now no data have been published on the epidemiology of respiratory NTM infections in Italy. The Italian registry of pulmonary NTM (IRENE) is an observational, multicenter, prospective, cohort study enrolling consecutive adult patients with either a NTM respiratory infection or NTM-PD. The coordinating center is located at the Pulmonary Department of the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. So far, more than 35 centers, including mainly pulmonary and infectious disease departments, joined the registry. The study is sponsored by the Policlinico Hospital in Milan. The study website is located at www.registroirene.it. Adult (\>=18 years) patients with all of the following are included in the registry: 1) at least one positive culture for any NTM species from any respiratory sample; 2) at least one positive culture for NTM isolated in the year prior the enrolment and/or prescribed NTM treatment in the year prior the enrolment; 3) Given consent to inclusion in the study. No exclusion criteria are applied to the study. Patients included in the registry are mainly recruited among pulmonary and ID out- and in-patient services. Adult cystic fibrosis, lung transplant, and tuberculosis clinics represent other recruitment centers. The registry has been developed to accept an unlimited number of patients and no deadlines have been decided. Patients are managed according to standard operating procedures implemented in each IRENE clinical center without any interference from the study team. A baseline case report form is collected at patient's enrolment including demographics, comorbidities, microbiological, laboratory, functional, radiological, clinical, and treatment data. Then, study investigators enter follow-up data on an annual basis. An IRENE biobank has also been developed within the network and linked to the clinical data of the registry. IRENE sites can collect samples, including blood, serum, plasma, respiratory specimens (sputum, induced sputum, tracheal aspirate, or bronchoalveolar lavage), urine, and NTM isolates at the first visit and during follow up on a voluntary basis.

Interventions

None listed

Sponsors

Niguarda Hospital
CollaboratorOTHER
Azienda Ospedaliera San Gerardo di Monza
CollaboratorOTHER
ASST Fatebenefratelli Sacco
CollaboratorOTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
CollaboratorOTHER
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
CollaboratorOTHER
University of Turin, Italy
CollaboratorOTHER
A.O.U. Città della Salute e della Scienza - Molinette Hospital
CollaboratorOTHER
Azienda Unità Locale Socio Sanitaria n.9 Treviso
CollaboratorOTHER
Ospedale Maggiore Di Trieste
CollaboratorOTHER
Azienda Ospedaliero-Universitaria di Modena
CollaboratorOTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
CollaboratorOTHER
Università degli Studi di Ferrara
CollaboratorOTHER
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
CollaboratorOTHER
Azienda Ospedaliero, Universitaria Pisana
CollaboratorOTHER
Azienda Ospedaliero-Universitaria Careggi
CollaboratorOTHER
Ospedale San Jacopo, Pistoia, Italy
CollaboratorUNKNOWN
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CollaboratorOTHER
Azienda Policlinico Umberto I
CollaboratorOTHER
Istituto Nazionale per le Malattie Infettive Spallanzani, Roma
CollaboratorUNKNOWN
Policlinico Universitario, Catania
CollaboratorOTHER
Azienda Ospedaliera Universitaria Policlinico G. Martino
CollaboratorOTHER
Azienda Ospedaliera Cosenza
CollaboratorOTHER
Azienda Ospedaliero Universitaria di Sassari
CollaboratorOTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(all of them): * Adult (\>=18 years) patients * At least one positive culture for any NTM species from any respiratory sample * At least one positive culture for NTM isolated in the year prior the enrolment and/or prescribed NTM treatment in the year prior the enrollment * Given consent to inclusion in the study.

Exclusion criteria

No

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients meeting the quality standards for NTM-PD care suggested by international guidelines (including the latest ERS 2017 guidelines)5 yearsThe number of patients with NTM-PD who have been managed or treated according to the recommendations published by international guidelines

Countries

Italy

Contacts

Primary ContactStefano Aliberti, MD
stefano.aliberti@unimi.it+390250320627

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026